Nautilus Biotechnology, Inc. (NAUT)
NASDAQ: NAUT · Real-Time Price · USD
0.8301
-0.0309 (-3.59%)
Apr 1, 2025, 4:00 PM EDT - Market closed

Company Description

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.

The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system designed to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples.

In addition, the company offers reagent kits, which are comprised of sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs.

Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Nautilus Biotechnology, Inc.
Nautilus Biotechnology logo
Country United States
Founded 2016
Industry Biotechnology
Sector Healthcare
Employees 155
CEO Sujal Patel

Contact Details

Address:
2701 Eastlake Avenue East
Seattle, Washington 98102
United States
Phone 206 333 2001
Website nautilus.bio

Stock Details

Ticker Symbol NAUT
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001808805
CUSIP Number 63909J108
ISIN Number US63909J1088
Employer ID 98-1541723
SIC Code 3826

Key Executives

Name Position
Sujal M. Patel Co-Founder, Chief Executive Officer, President, Secretary and Director
Dr. Parag Mallick Ph.D. Co-Founder, Chief Scientist and Director
Anna Mowry Chief Financial Officer and Treasurer
Matthew B. Murphy ESQ. General Counsel
Chris Blessington Vice President of Corporate Marketing and Communications
Kentaro Suzuki Chief Marketing Officer
Gwen E. Weld Chief People Officer
Nick A. Nelson Chief Business Officer and Senior Vice President of Business Development
Dr. Subra Sankar Ph.D. Senior Vice President of Product Development

Latest SEC Filings

Date Type Title
Mar 5, 2025 SCHEDULE 13D/A Filing
Mar 5, 2025 SCHEDULE 13D/A Filing
Feb 27, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Jan 31, 2025 SCHEDULE 13D/A Filing
Jan 31, 2025 8-K Current Report
Dec 17, 2024 144 Filing
Dec 9, 2024 144 Filing
Dec 3, 2024 144 Filing